Bio Path reported $199K in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Alterity Therapeutics Limited AUD 1.45M 703.96K Dec/2025
Baxter International USD 761M 53M Dec/2025
Bio Path USD 199K 300K Sep/2025
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.21M 120K Dec/2025
CSL USD 1.23B 498M Dec/2025
Grifols EUR 320.45M 12.65M Dec/2025
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025